Dorscheid, Delbert R.

ASCENT – Asthma control in severe asthma patients treated with tezepelumab: a prospective, observational, real-world evidence study

This study involves primary data collection within real-world settings of participants who start treatment with tezepelumab for severe uncontrolled asthma. This study will complement evidence obtained from randomized controlled trials and provide new data focusing on the holistic and patient reported outcomes.

SUNRISE – A randomised, double-blind, parallel-group, placebo-controlled 28-week phase 3 efficacy & safety study of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

The purpose of this study is to demonstrate the ability of tezepelumab, compared with placebo, to reduce oral corticosteroid (OCS) use in adults with severe asthma being treated with maintenance OCS in combination with high dose inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA), with or without other asthma controller therapies, while maintaining asthma control.

ATLAS – A randomized, double-blind, placebo controlled study assessing the long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate to severe asthma

The goal of this study is to determine whether patients treated with dupilumab demonstrate prevention or slowing of lung function decline over a period of 3- years compared to standard of care therapy. All participants in the study will receive dupilumab or placebo on top of the standard of care therapy, which will consist of medium to high dose ICS in combination with a second controller (eg, LABA, LTRA) ± a third controller.

KALOS – A variable length efficacy & safety study to assess an inhaled, fixed-dose, triple-combination of Budesonide/ Glycopyrronium/ Formoterol Fumarate in adults with poorly controlled asthma

This study is designed to check the safety and effectiveness of a 3 drug inhaler for people who do not have good asthma control. The study will compare two different doses of the 3 drug inhaler against a similar 3 drug combination. The study participants will be involved for up to 64 weeks.